Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: Results of the ONTARGET/TRANSCEND studies

Journal of Internal Medicine

Volumn 278, Issue 3, 2015, Pages 303-312

  Bohm M ^a   Schumacher, H ^b   Linz, D ^a   Reil, J C ^a   Ukena, C ^a   Lonn, E ^c   Teo, K ^c   Sliwa, K ^d   Schmieder, R E ^e   Sleight, P ^f   Yusuf, S ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Cardiovascular disease risk; Heart rate

Indexed keywords

DIGITALIS; DILTIAZEM; VERAPAMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW-ONSET ATRIAL FIBRILLATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; SMOKING; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; ATRIAL FIBRILLATION; BLOOD PRESSURE; COMPLICATION; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; HEART RATE; HUMANS; MIDDLE AGED; VASCULAR DISEASES;

EID: 84938746352     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12373     Document Type: Article

References (38)

1. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
2. Manolis AJ, Rosei EA, Coca A et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012; 30: 239-52.
3. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-8.
4. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7: 999-1007.
5. Chen J, Wasmund SL, Hamdan MH. Back to the future: the role of the autonomic nervous system in atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 413-21.
6. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002; 105: 2753-9.
7. Tomita T, Takei M, Saikawa Y et al. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol 2003; 14: 559-64.
8. Grundvold I, Skretteberg PT, Liestøl K et al. Low heart rates predict incident atrial fibrillation in healthy middle-aged men. Circ Arrhythm Electrophysiol 2013; 6: 726-31.
9. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-34.
10. Lonn EM, Rambihar S, Gao P et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 2014; 103: 149-59.
11. Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-94.
12. Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors-a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil 2010; 17: 100-5.
13. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
14. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors. Lancet 2008; 372: 1174-83.
15. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551-61.
16. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711-6.
17. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328: 533-7.
18. Leeper NJ, Dewey FE, Ashley EA et al. Prognostic value of heart rate increase at onset of exercise testing. Circulation 2007; 115: 468-74.
19. Zimmermann M, Kalusche D. Fluctuation in autonomic tone is a major determinant of sustained atrial arrhythmias in patients with focal ectopy originating from the pulmonary veins. J Cardiovasc Electrophysiol 2001; 12: 285-91.
20. Fioranelli M, Piccoli M, Mileto GM et al. Analysis of heart rate variability five minutes before the onset of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1999; 22: 743-9.
21. Bernardi L, Ricordi L, Lazzari P et al. Impaired circadian modulation of sympathovagal activity in diabetes. Circulation 1992; 86: 1443-52.
22. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009; 103: 1572-7.
23. Ellestad MH. Chronotropic incompetence. The implications of heart rate response to exercise (compensatory parasympathetic hyperactivity?). Circulation 1996; 93: 1485-7.
24. Hunter RJ, Liu Y, Lu Y, Wang W, Schilling RJ. Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 351-60.
25. Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 2006; 8: 943-9.
26. Bertaglia E, Zoppo F, Bonanno C, Pellizzari N, Frigato N, Pascotto P. Autonomic modulation of the sinus node following electrical cardioversion of persistent atrial fibrillation: relation with early recurrence. Int J Cardiol 2005; 102: 219-23.
27. Kanoupakis EM, Manios EG, Mavrakis HE, Kaleboubas MD, Parthenakis FI, Vardas PE. Relation of autonomic modulation to recurrence of atrial fibrillation following cardioversion. Am J Cardiol 2000; 86: 954-8.
28. Thelle DS, Selmer R, Gjesdal K et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309 540 men and women. Heart 2013; 99: 1755-60.
29. Levy MN. Brief reviews: sympathetic-parasympathetic interactions in the heart. Circ Res 1971; 29: 437-45.
30. Yang T, Levy MN. Sequence of excitation as a factor in sympathetic-parasympathetic interactions in the heart. Circ Res 1992; 71: 898-905.
31. Yang T, Levy MN. The phase-dependency of the cardiac chronotropic responses to vagal stimulation as a factor in sympathetic-vagal interactions. Circ Res 1984; 54: 703-10.
32. Okin PM, Wachtell K, Kjeldsen SE et al. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol 2008; 1: 337-43.
33. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375: 938-48.
34. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
35. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation 2011; 123: 1010-20.
36. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
37. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, for the SIGNIFY Investigators. Ivabradine in stable coronary artery disease in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091-99.
38. den Hoed M, Eijgelsheim M, Esko T et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013; 45: 621-31.